NASDAQ:TROVTrovaGene Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding TrovaGene Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.91 +0.10 (+12.35 %) (As of 04/9/2020 04:00 PM ET) Add Compare Share Today's Range$0.79Now: $0.91▼$0.9250-Day Range$0.74MA: $1.15▼$1.6952-Week Range$0.70Now: $0.91▼$4.20Volume224,223 shsAverage Volume178,186 shsMarket Capitalization$9.29 millionP/E RatioN/ADividend YieldN/ABeta0.82 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTrovaGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.50, TrovaGene has a potential upside of 1,493.4% from its current price of $0.91.Amount of Analyst CoverageTrovaGene has only been the subject of 1 research reports in the past 90 days. Previous Next 2.9 Community Rank Outperform VotesTrovaGene has received 402 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrovaGene has received 296 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrovaGene has received 57.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote “Outperform” if you believe TROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTrovaGene does not currently pay a dividend.Dividend GrowthTrovaGene does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, TrovaGene insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.60% of the stock of TrovaGene is held by insiders.Percentage Held by InstitutionsOnly 9.99% of the stock of TrovaGene is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for TrovaGene are expected to decrease by -100.00% in the coming year, from ($4.02) to $0.00 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TrovaGene is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TrovaGene is -0.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrovaGene has a P/B Ratio of 0.97. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.41 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TROV Previous Symbol CUSIPN/A CIK1213037 Webhttp://www.trovagene.com/ Phone858-952-7570Debt Debt-to-Equity Ratio0.12 Current Ratio2.37 Quick Ratio2.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$250,000.00 Price / Sales37.16 Cash FlowN/A Price / Cash FlowN/A Book Value$0.94 per share Price / Book0.97Profitability EPS (Most Recent Fiscal Year)($2.80) Net Income$-16,410,000.00 Net Margins-3,688.31% Return on Equity-202.00% Return on Assets-122.92%Miscellaneous EmployeesN/A Outstanding Shares10,210,000Market Cap$9.29 million Next Earnings Date5/5/2020 (Estimated) OptionableOptionable Receive TROV News and Ratings via Email Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TROV Rates by TradingView TrovaGene (NASDAQ:TROV) Frequently Asked Questions How has TrovaGene's stock been impacted by COVID-19 (Coronavirus)? TrovaGene's stock was trading at $1.11 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, TROV shares have decreased by 18.0% and is now trading at $0.91. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of TrovaGene? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TrovaGene. When is TrovaGene's next earnings date? TrovaGene is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for TrovaGene. How were TrovaGene's earnings last quarter? TrovaGene Inc (NASDAQ:TROV) announced its earnings results on Thursday, February, 27th. The medical research company reported ($0.51) EPS for the quarter, topping the Zacks' consensus estimate of ($0.65) by $0.14. The medical research company earned $0.09 million during the quarter. TrovaGene had a negative net margin of 3,688.31% and a negative return on equity of 202.00%. View TrovaGene's earnings history. When did TrovaGene's stock split? How did TrovaGene's stock split work? TrovaGene shares reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split. What price target have analysts set for TROV? 2 Wall Street analysts have issued twelve-month price targets for TrovaGene's shares. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's stock price to reach $14.50 in the next year. This suggests a possible upside of 1,493.4% from the stock's current price. View analysts' price targets for TrovaGene. What are Wall Street analysts saying about TrovaGene stock? Here are some recent quotes from research analysts about TrovaGene stock: 1. According to Zacks Investment Research, "Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. " (3/21/2020) 2. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019) Has TrovaGene been receiving favorable news coverage? Media stories about TROV stock have trended very negative recently, InfoTrie Sentiment reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TrovaGene earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave news coverage about the medical research company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news aboutTrovaGene. Who are some of TrovaGene's key competitors? Some companies that are related to TrovaGene include aTyr Pharma (LIFE), Allena Pharmaceuticals (ALNA), Curis (CRIS), Entera Bio (ENTX), BioCardia (BCDA), Outlook Therapeutics (OTLK), Titan Pharmaceuticals (TTNP), CytRx (CYTR), TRACON Pharmaceuticals (TCON), Genetic Technologies (GENE), Vitro Diagnostics (VODG), Enzon Pharmaceuticals (ENZN), Seneca Biopharma (SNCA), Gene Biotherapeutics (CRXM) and Neuralstem (CUR). What other stocks do shareholders of TrovaGene own? Based on aggregate information from My MarketBeat watchlists, some companies that other TrovaGene investors own include XOMA (XOMA), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO), Micron Technology (MU), Zynerba Pharmaceuticals (ZYNE), Alnylam Pharmaceuticals (ALNY), Alibaba Group (BABA), NVIDIA (NVDA), Exelixis (EXEL) and Protalix Biotherapeutics (PLX). Who are TrovaGene's key executives? TrovaGene's management team includes the following people: Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)Dr. Mark Erlander, Chief Scientific Officer (Age 59)Ms. Elizabeth Anderson, VP of Fin. & Admin.Mr. George Samuel, VP & Gen. CounselMs. Vicki Kelemen, VP of Corp. Communications What is TrovaGene's stock symbol? TrovaGene trades on the NASDAQ under the ticker symbol "TROV." How do I buy shares of TrovaGene? Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is TrovaGene's stock price today? One share of TROV stock can currently be purchased for approximately $0.91. How big of a company is TrovaGene? TrovaGene has a market capitalization of $9.29 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis. View additional information about TrovaGene. What is TrovaGene's official website? The official website for TrovaGene is http://www.trovagene.com/. How can I contact TrovaGene? TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected] This page was last updated on 4/9/2020 by MarketBeat.com StaffFeatured Article: Penny Stocks, Risk and Reward Factors
